Progress in treatment of rare cancers named "Advance of the Year" by ASCO
The American Society of Clinical Oncology (ASCO) has named “Progress in Treating Rare Cancers” as the “Advance of the Year” in its annual Clinical Cancer Advances report released on Thursday.According to the report, rare cancers account for about 20% of all cancers diagnosed annually in the United States. But progress in their treatment has not kept pace with the more common types
To continue reading this article
Continue reading your article with a eMediNexus account.